

(19) World Intellectual Property
Organization
International Bureau



WIPO | PCT



(10) International Publication Number

WO 2025/125898 A9

(43) International Publication Date
19 June 2025 (19.06.2025)

(51) International Patent Classification:

C07K 16/18 (2006.01) G01N 33/68 (2006.01)
A61P 25/28 (2006.01) A61K 39/00 (2006.01)
C07K 16/28 (2006.01)

(21) International Application Number:

PCT/IB2024/000719

(22) International Filing Date:

13 December 2024 (13.12.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

2319255.2	15 December 2023 (15.12.2023)	GB
63/669,394	10 July 2024 (10.07.2024)	US
63/716,754	06 November 2024 (06.11.2024)	US

(71) Applicant: **ALCHEMAB THERAPEUTICS LTD**
[GB/GB]; East Side Office 1.02, Kings Cross, London N1C 4AX (GB).

(72) Inventors: **MCCARTHY, James**; c/o Alchemab Therapeutics Ltd, East Side Office 1.02, Kings Cross, London, N1C 4AX (GB). **LEGG, Sandrine**; c/o Alchemab Therapeutics Ltd, East Side Office 1.02, Kings Cross, London, N1C 4AX (GB). **LEWIS, Giles**; c/o Alchemab Therapeutics Ltd, East Side Office 1.02, Kings Cross, London, N1C 4AX (GB).

apeutics Ltd, East Side Office 1.02, Kings Cross, London, N1C 4AX (GB). **MITCHELL, Laura, Sophie**; c/o Alchemab Therapeutics Ltd, East Side Office 1.02, Kings Cross, London, N1C 4AX (GB). **BARTON, Justin**; c/o Alchemab Therapeutics Ltd, East Side Office 1.02, Kings Cross, London, N1C 4AX (GB). **POVALL, Chelsea**; c/o Alchemab Therapeutics Ltd, East Side Office 1.02, Kings Cross, London, N1C 4AX (GB). **JENKINS KNIGHT, Emma, Louise**; c/o Alchemab Therapeutics Ltd, East Side Office 1.02, Kings Cross, London, N1C 4AX (GB). **MIN-TER, Ralph, Raymond**; c/o Alchemab Therapeutics Ltd, East Side Office 1.02, Kings Cross, London, N1C 4AX (GB). **FINCH, Donna**; c/o Alchemab Therapeutics Ltd, East Side Office 1.02, Kings Cross, London, N1C 4AX (GB). **SIDOR, Michelle**; c/o Alchemab Therapeutics Ltd, East Side Office 1.02, Kings Cross, London, N1C 4AX (GB). **GALSON, Jacob, Daniel**; c/o Alchemab Therapeutics Ltd, East Side Office 1.02, Kings Cross, London, N1C 4AX (GB). **OSBOURN, Jane, Katharine**; c/o Alchemab Therapeutics Ltd, East Side Office 1.02, Kings Cross, London, N1C 4AX (GB). **DIAS DO NASCIMENTO, Jorge, Norman**; c/o Alchemab Therapeutics Ltd, East Side Office 1.02, Kings Cross, London, N1C 4AX (GB). **KOLASINSKA-ZWIERZ, Paulina, Maria**; c/o Alchemab Therapeutics Ltd, East Side Office 1.02, Kings Cross, London, N1C 4AX (GB). **GHAWTHORNE, William, James**; c/o

(54) Title: ANTI-UNC5C ANTIBODIES AND USES THEREOF

ATL6532 and ATL6533 as Capture Antibodies,
Detection with AF1005




Fig. 19A

(57) Abstract: Assays for detecting the level of soluble UNC5C in a biological fluid sample from a patient, and the use of such levels as markers of neurodegenerative disease presence and/or severity are described. Antibodies and fragments thereof capable of binding to UNC5C, and the use of such antibodies for detecting the level of soluble UNC5C in a biological fluid sample from a patient are also described, as well as methods for detecting the level of soluble UNC5C in a biological fluid sample from a patient using anti-UNC5C antibodies in a clinical context.

[Continued on next page]



WO 2025/125898 A9

Alchemab Therapeutics Ltd, East Side Office 1.02, Kings Cross, London, N1C 4AX (GB). **GRAVES, Helen**; c/o Alchemab Therapeutics Ltd, East Side Office 1.02, Kings Cross, London, N1C 4AX (GB).

(74) **Agent: MEWBURN ELLIS LLP** et al.; Aurora Building, Counterslip, Bristol BS1 6BX (GB).

(81) **Designated States** (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(88) **Date of publication of the revised international search report:**

02 October 2025 (02.10.2025)

(15) **Information about Correction:**

see Notice of 02 October 2025 (02.10.2025)